Fetal haemoglobin induction in sickle cell disease

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Fetal hemoglobin (HbF) induction is a therapeutic strategy for sickle cell disease (SCD).
• Limited understanding of gamma-globin gene regulation hinders the development of novel HbF-inducing agents.
• Genetic studies implicate BCL11A and HBS1L-MYB in HbF regulation.

Purpose of the Study:

• To review the current understanding of gamma-globin regulation in the context of HbF induction for SCD.
• To discuss the challenges and progress in developing pharmacological and gene-editing therapies for SCD.

Main Methods:

• Review of genome-wide association studies (GWAS) identifying genetic regulators of HbF.
• Analysis of functional studies on key regulatory proteins like BCL11A, MYB, and KLF1.
• Evaluation of current clinical trials for HbF-inducing agents and gene-editing therapies.

Main Results:

• BCL11A and HBS1L-MYB variants are associated with varying HbF levels.
• Key transcription factors (BCL11A, MYB, KLF1) play crucial roles in gamma-globin regulation.
• Hydroxycarbamide is the sole established pharmacological therapy; new agents and gene therapies are in development.

Conclusions:

• Despite progress, effective pharmacological treatments for SCD remain limited.
• Gene editing of hematopoietic stem cells offers potential but faces technical and safety challenges.
• Further research into gamma-globin regulation is essential for advancing SCD therapeutics.